



Vaccine Integrity Project

Program Overview and Update

Overview

- History of the Project
- Overview, Programs
- Ongoing Activities
- Discussion



Visit our website



Looking back: Concerns about the potential threats back in January 2025

- Threats to vaccine access
- Challenges to the body of evidence, especially safety and effectiveness
- Weakened ACIP recommendations
- Vaccines removed from Vaccines for Children program, coverage lost
- Vaccine and provider liability protection
- Vaccine research is defunded
- Vaccine programs funded by CDC are reduced or eliminated
- FDA regulations changes making it harder for new vaccines to come to market
- Vaccine Injury Compensation Program is threatened
- Insurers no longer covering vaccines



Background

- Funding provided by Alumbra to kickstart the effort
- Formed Steering Committee in April 2025 to guide first phase of work
- Facilitated listening sessions and discussions with over 60 individuals in May 2025 to understand what vaccine and vaccination activities could be performed outside the USG
 - [Interim update](#) released in June 2025
 - [Final report](#) released in July 2025
- Delivery of the final report concluded the exploratory phase



Key Recommendations from Listening Sessions

- Increasing Communication and Information Dissemination for Today's Environment
- Developing and Disseminating Clinical Tools and Guidelines for the Entire Healthcare System
- Building an Overarching Coalition for Strategy and Alignment
- Stabilizing the Vaccine Safety System
- Safeguarding Insurance Coverage for Vaccines
- Maintaining the Nation's Vaccination Infrastructure
- Providing Assistance to State Health Departments
- Continuing the Flow of Data for Decision-making

5




Our Focus Areas

- **Summarizing and Disseminating Scientific Evidence:** Engaging with health care providers, the public health community, and medical societies, the Vaccine Integrity Project conducts comprehensive reviews of scientific evidence to inform vaccine recommendations.
- **Rapidly Responding:** In response to misleading and inaccurate claims, the Vaccine Integrity Project monitors and addresses inaccurate vaccine- and public health-related information in real time.
- **Fostering Collaboration and Visibility:** The scale and complexity of the challenges demand ongoing collaboration and coordinated action across the vaccine ecosystem. The Project regularly convenes to support alignment and help prioritize and address emerging issues in real time.

6



The Project: Where we have been and where we are going



2025-26 Respiratory Season Evidence Review

- [Evidence base](#) was developed
- [Webinar](#) held to share findings
- [Interactive tool](#), data access, and [executive summary](#) launched
- [Manuscript](#) published

The NEW ENGLAND JOURNAL of MEDICINE

SPECIAL ARTICLE

Updated Evidence for Covid-19, RSV, and Influenza Vaccines for 2025–2026

J. Scott,¹ M.S. Abers,² H.K. Marwah,³ N.C. McCann,⁴ E.A. Meyerowitz,² A. Richterman,⁵ D.F. Fleming,⁶ E.J. Holmes,⁶ L.E. Moat,⁶ S.G. Redepenning,⁶ E.A. Smith,⁶ C.J. Stoddart,⁶ M.E. Sundaram,⁷ A.K. Ulrich,⁶ C. Alba,⁸ C.J. Anderson,⁶ M.K. Arpey,⁶ E. Borre,⁹ J. Ladines-Lim,⁵ A.J. Mehr,⁶ K. Rich,⁹ C. Watts,⁵ N.E. Basta,¹⁰ J. Jarolimova,¹¹ R.P. Walensky,¹² and C.M. Dugdale¹³



Read the publication,
linked here

VACCINE
INTEGRITY
PROJECT


Hepatitis B at Birth Evidence Review

- [Report](#) was posted online
- Publication in [Pediatrics](#)
- [Interactive data tool](#) was launched



*Read the publication,
linked here*

The review found no benefit related to vaccine safety or protection of a delayed first dose compared with vaccination at birth; critical risks of changing current US recommendations were identified.




HPV Evidence Review

The Vaccine Integrity Project’s comprehensive review of peer-reviewed evidence related to human papillomavirus (HPV) vaccines found that they **remain highly safe and effective** in preventing cervical cancer, precancerous lesions, and persistent HPV infection, with **emerging evidence supporting the potential effectiveness of a single-dose regimen** for key outcomes in women.

- [Report](#) was published online
- [Executive summary](#) posted
- [Interactive data tool](#) was launched
- Peer-reviewed publication underway

Select analysis type to see a forest plot summary of findings



TDAP in Pregnancy Evidence Review

Safety

- Collected & analyzed data on pre-specified safety outcomes, including neonatal mortality, congenital anomalies, NICU admission, neonatal sepsis, growth restriction, low birth weight
- No meaningful increase in adverse outcomes during infancy with Tdap exposure during pregnancy compared to no Tdap



Use the tool, linked here

Effectiveness

- Tdap during pregnancy likely reduces risk of infection in infants
- Tdap during pregnancy likely reduces risk of pertussis-related hospitalization and ED visits in infants
- Data suggests decreased risk, with more benefit in areas of higher disease prevalence



2026-27 Respiratory Season

Collaboration was launched early in 2026 **with the American Medical Association.**

Guiding principles:

- Engage medical societies, public health leaders, insurers, academic experts, etc., early and throughout the process.
- Produce a scientifically rigorous evidence review across RSV, influenza, and COVID-19 immunizations.
- Maintain strong communications and transparency.
- Deliver practical resources for clinicians, parents, and the public.
- Designed to help meet the needs and priorities outlined by the medical specialty societies.

DELIBERATIVE DRAFT FOR DECISION-MAKING



2026-27 Respiratory Season (cont.)

GOAL: Coordinated and unified release of evidence and recommendations by the participating societies before the start of respiratory season the first week of September.

Deliverables:

- Core deliverables include evidence review, interactive data tools, convening summaries, clinician tools, and dissemination webinars, and other communication forums.
- Once the review is complete and recommendations are released by the societies, follow on outputs may include additional webinars, public dashboards, infographics, and communication toolkits for clinicians, payors, public health leaders, and the general public; needs assessment underway.
- Publicly post intermittent updates over the course of this project.

DELIBERATIVE DRAFT FOR DECISION-MAKING



Respiratory Recommendation Crosswalk

	Pediatrics (0-18 years)	Adults (19+ years)	Immuno- compromised	Healthcare Personnel*	Pregnancy
RSV	AAP	AAFP	IDSA	AAFP	ACOG
Flu	AAP	AAFP	IDSA	AAFP	ACOG
COVID-19	AAP	AAFP	IDSA	AAFP	ACOG

*Assistance from IDSA

DELIBERATIVE DRAFT FOR DECISION-MAKING



Respiratory Deliverable: Needs Assessment

The AMA is conducting research to help inform development of additional vaccination recommendation-related resources (May - June)

Research objectives:

1. Identify knowledge gaps related to COVID-19, influenza, and RSV immunization recommendations across key populations.

2. Assess physicians' confidence, comfort, and current practices when discussing vaccines with patients.

3. Understand barriers physicians face in vaccine communication, including recommendation complexity and patient hesitancy.


4. Determine physicians' informational needs and preferred formats for educational and communication tools.

DELIBERATIVE DRAFT FOR DECISION-MAKING



Communication Efforts

- Collaboration with *the Evidence Collective* and *Unbiased Science* to address inaccurate vaccine information and improve access to evidence-based public health information
- Continuous publication of Viewpoints commentaries to challenge inaccurate federal vaccine information
- Enhanced digital and social media presence



DELIBERATIVE DRAFT FOR DECISION-MAKING





Thank You



CIDRAP—Center for Infectious Disease Research & Policy
Research & Innovation Office, University of Minnesota,
Minneapolis, MN
(612) 626-6770
cidrap@umn.edu
vaxintegrity.cidrap.umn.edu

DELIBERATIVE DRAFT FOR DECISION-MAKING